Regeneron Pharmaceuticals faced a significant setback in the market as legal troubles loomed over its oncology pipeline.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) saw its stock price drop by 2.47% during yesterday’s trading session, closing at CA$774.11. This decline was largely due to the announcement of federal securities class action lawsuits related to its Fianlimab-Libtayo trial.
Advertisement
Regeneron Pharmaceuticals Inc
REGN.US
REGN.US
Regeneron Pharmaceuticals Inc
WealthAwesomeMarket cap
$76.86B
P/E
18.5x
Div. yield
0.49%
Div. / share
$3.64
52W high
$859.34
52W low
$551.04
1W change
+1.54%
Beta
0.15
Analyst Price Targets
Based on 27 analysts covering REGN · as of Oct 12, 2026
Wall Street analysts forecast REGN stock price to rise 15.1% over the next 12 months.
Consensus
Buy4.15 / 5.00
Avg. Target
C$859.04
+15.1% Upside
Previously C$856.23 on Oct 9, 2026
Current Price
C$746.54
Last close
Analyst Breakdown (27 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on REGN's historical volatility
30-Day Vol
28.3%
Annualized
90-Day Vol
29.2%
Annualized
Trend (90d)
+40.4%
Annualized drift
90d Mean
C$862.28
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$783.28 | C$710.45 – C$863.58 |
| 60 trading days | C$821.83 | C$715.88 – C$943.46 |
| 90 trading days | C$862.28 | C$728.17 – C$1021.08 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep a close eye on the ongoing legal issues surrounding Regeneron, as they introduce uncertainty into the company's future pipeline and revenue projections.
2.47% Decline
Regeneron’s stock fell by 2.47% yesterday, reflecting investor anxiety over legal challenges that could impact its future earnings.
Bull case
Despite the recent legal challenges, Regeneron has a strong product lineup, especially in eye diseases, and its pipeline could still offer significant long-term growth potential.
Bear case
The lawsuits raise serious concerns about Regeneron's management practices and the viability of its oncology products. This could lead to further declines in investor confidence and stock performance.
Advertisement
Legal Troubles Impacting Investor Sentiment
The recent filing of federal securities class action lawsuits against Regeneron has raised serious concerns among investors. The lawsuits allege that the company misled investors about the design and clinical prospects of its Phase III Fianlimab-Libtayo oncology trial. These claims have cast doubt on Regeneron’s credibility and could hinder its ability to attract future investments.
Pipeline Risks and Market Dependence
Regeneron’s business model heavily relies on the success of its key products, including Dupixent and EYLEA. With increasing competition and pricing pressures, the company faces significant risks. The new legal challenges only add to these issues, as they could disrupt the development of promising therapies and ultimately impact revenue streams.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
